High dose cyclophosphamide and total body irradiation (TBI) are frequently used as conditioning for BMT. Initial regimens included a single fraction of TBI, with doses varying from 7.5-10Gy, but this was associated with a high incidence of late sequelae including multiple endocrinopathies 1. A fractionated irradiation course over 3-4 days of a higher total dose, 12-15Gy, of TBI is now used 1,2. Successfully treated patients with childhood cancer have an increased risk, of developing second tumours. We describe a patient successfully treated for AML who developed multiple endocrine dysfunction and a second benign ovarian tumour. ' (Accepted 3I August 1995)
HISTORY
A 8.4-year-old girl was initially treated for acute myeloid leukaemia (AML) with standard chemotherapy and allogenic BMT conditions with cyclophosphamide (60mg/kg/day on 2 consecutive days) and 10 Gy single fraction TBI. Eighteen months after TBI, an initial endocrine assessment revealed an exaggerated TSH response to intravenous TRH, with normal thyroid function, and a borderline GH response (GH peak value 18mUll) to a 'primed' insulin tolerance test. At 12 years there was spontaneous onset of breast development and menarche occurred one year later. Her pattern of growth was suboptimal, GH treatment was commenced and a final height of 154.8 ems was attained which was in the lower range of her genetic target (152.7-170.5 em). Her periods were regular over the first 3 years but at 16 years she presented with secondary amennorhoea. At that time she was overweight (body mass index: 26 kg/m 2 ) . Basal gonadotrophin values were not raised with no abnormalities in the LH/FSH ratio, oestrogen levels were low and neither ovarian cystic activity nor polycystic ovaries were demonstrated on pelvic ultrasound imaging. Oestrogen/progesterone replacement treatment was recommended but was not complied with. Thirty months later, she was also found to be hypertensive (blood pressure 14D systolic, 100 diastolic, mmHg) in addition to secondary amenorrhoea and within 3 months developed progressive virilization with hirsutism and acne. Hyperandrogenism, with elevated testosterone (4.5 nmolll, adult female range 0.8-3.0) androstenedione (13.8 nmolll, normal range 2-10) and DHEAS (12.8 nmolll, normal range 2.7-8.7) values were biochemically confirmed. Oestradiol levels were below 250 pmolll on several different occasions. Pulsatile gonadotrophin secretion was abnormal for the patient's stage of sexual maturation (Figure 1 ). Pelvic imaging studies showed an enhancing, partly calcified,mass (3 X 5 X 5 em) in the right side of the pelvis. At laparatomy both ovaries were removed and a sclerosing stromal tumour was found in the right ovary. ovary was atrophic. Normalization of androgenic hormones, blood pressure and regression of virilizingfeatures followed the operation. The patient was then treated with replacement oestrogen and progesterone. The final diagnosis for her secondary amenorrhoea was ovarian failure secondary to TBI and suppression of gonadotrophin secretion secondary to high androgen secretion by the ovarian tumour.
DISCUSSION
The occurrence of secondary amenorrhoea after single fraction TBI may be due to an early menopause. However this case illustrates how other diagnoses should be considered. Cor xisting gonadotrophin insufficiency secondary to the suppression by the hyperandrogenic state and/or irradiation of the pituitary gland occurred in our case so that raised gonadotrophin levels were not found despite gonadal failure. Peripheral testosterone conversion into oestradiol or coexisting production of oestradiol from the ovarian tumour may have allowed the conservation of secondary sexual characteristics. A sclerosing ovarian tumour is an uncommon benign tumour, which has been associated with oestrogen and/ or androgen production-". It has not previously been described in association with acute leukaemia and no family history of tumour predisposition was present in our case. The potential mitogenic effectof growth hormone treatment may cause concern when GH is used in patients with a previous history of leukaemia. However; data on relapse rates of patients with acute leukaemia or brain tumours treated with GH5 do not support the hypothesis of GH induced neoplasia.
In conclusion, life long follow-up of patients treated for childhood cancer is mandatory as there is a significant risk of developing multiple endocrinopathies and/or secondary tumours. The relationship between the latter and GH treatment remains unknown.
'
